RESUMEN
CONTEXT: Multiple observational studies have reported an inverse relationship between 25-hydroxyvitamin D concentrations (25(OH)D) and type 2 diabetes (T2D). However, the results of short- and long-term interventional trials concerning the relationship between 25(OH)D and T2D risk have been inconsistent. OBJECTIVES AND METHODS: To evaluate the causal role of reduced blood 25(OH)D in T2D, here we have performed a bidirectional Mendelian randomization study using 59,890 individuals (5,862 T2D cases and 54,028 controls) from European and Asian Indian ancestries. We used six known SNPs, including three T2D SNPs and three vitamin D pathway SNPs, as a genetic instrument to evaluate the causality and direction of the association between T2D and circulating 25(OH)D concentration. RESULTS: Results of the combined meta-analysis of eight participating studies showed that a composite score of three T2D SNPs would significantly increase T2D risk by an odds ratio (OR) of 1.24, p = 1.82 × 10-32; Z score 11.86, which, however, had no significant association with 25(OH)D status (Beta -0.02nmol/L ± SE 0.01nmol/L; p = 0.83; Z score -0.21). Likewise, the genetically instrumented composite score of 25(OH)D lowering alleles significantly decreased 25(OH)D concentrations (-2.1nmol/L ± SE 0.1nmol/L, p = 7.92 × 10-78; Z score -18.68) but was not associated with increased risk for T2D (OR 1.00, p = 0.12; Z score 1.54). However, using 25(OH)D synthesis SNP (DHCR7; rs12785878) as an individual genetic instrument, a per allele reduction of 25(OH)D concentration (-4.2nmol/L ± SE 0.3nmol/L) was predicted to increase T2D risk by 5%, p = 0.004; Z score 2.84. This effect, however, was not seen in other 25(OH)D SNPs (GC rs2282679, CYP2R1 rs12794714) when used as an individual instrument. CONCLUSION: Our new data on this bidirectional Mendelian randomization study suggests that genetically instrumented T2D risk does not cause changes in 25(OH)D levels. However, genetically regulated 25(OH)D deficiency due to vitamin D synthesis gene (DHCR7) may influence the risk of T2D.
Asunto(s)
Diabetes Mellitus Tipo 2 , Deficiencia de Vitamina D , Pueblo Asiatico/genética , Diabetes Mellitus Tipo 2/genética , Humanos , Análisis de la Aleatorización Mendeliana , Polimorfismo de Nucleótido Simple , Vitamina D , Deficiencia de Vitamina D/genéticaRESUMEN
BACKGROUND: Hypertriglyceridemia has emerged as a critical coronary artery disease (CAD) risk factor. Rare loss-of-function (LoF) variants in apolipoprotein C-III have been reported to reduce triglycerides (TG) and are cardioprotective in American Indians and Europeans. However, there is a lack of data in other Europeans and non-Europeans. Also, whether genetically increased plasma TG due to ApoC-III is causally associated with increased CAD risk is still unclear and inconsistent. The objectives of this study were to verify the cardioprotective role of earlier reported six LoF variants of APOC3 in South Asians and other multi-ethnic cohorts and to evaluate the causal association of TG raising common variants for increasing CAD risk. METHODS: We performed gene-centric and Mendelian randomization analyses and evaluated the role of genetic variation encompassing APOC3 for affecting circulating TG and the risk for developing CAD. RESULTS: One rare LoF variant (rs138326449) with a 37% reduction in TG was associated with lowered risk for CAD in Europeans (p = 0.007), but we could not confirm this association in Asian Indians (p = 0.641). Our data could not validate the cardioprotective role of other five LoF variants analysed. A common variant rs5128 in the APOC3 was strongly associated with elevated TG levels showing a p-value 2.8 × 10- 424. Measures of plasma ApoC-III in a small subset of Sikhs revealed a 37% increase in ApoC-III concentrations among homozygous mutant carriers than the wild-type carriers of rs5128. A genetically instrumented per 1SD increment of plasma TG level of 15 mg/dL would cause a mild increase (3%) in the risk for CAD (p = 0.042). CONCLUSIONS: Our results highlight the challenges of inclusion of rare variant information in clinical risk assessment and the generalizability of implementation of ApoC-III inhibition for treating atherosclerotic disease. More studies would be needed to confirm whether genetically raised TG and ApoC-III concentrations would increase CAD risk.
Asunto(s)
Apolipoproteína C-III/genética , Enfermedad de la Arteria Coronaria/genética , Variación Genética , Anciano , Alelos , Enfermedad de la Arteria Coronaria/etnología , Europa (Continente)/epidemiología , Femenino , Estudios de Asociación Genética , Genotipo , Heterocigoto , Humanos , India/epidemiología , Masculino , Análisis de la Aleatorización Mendeliana , Persona de Mediana Edad , Mutación , Riesgo , Análisis de Secuencia de ADN , Triglicéridos/sangreRESUMEN
The increasing burden of obesity worldwide and its effect on cardiovascular disease (CVD) risk is an opportunity for evaluation of preventive approaches. Both obesity and CVD have a genetic background and polymorphisms within genes which enhance expression of variant proteins that influence CVD in obesity. Genome-based prediction may therefore be a feasible strategy, but the identification of genetically driven risk factors for CVD manifesting as clinically recognized phenotypes is a major challenge. Clusters of such risk factors include hyperglycaemia, hypertension, ectopic liver fat, and inflammation. All involve multiple genetic pathways having complex interactions with variable environmental influences. The factors that make significant contributions to CVD risk include altered carbohydrate homeostasis, ectopic deposition of fat in muscle and liver, and inflammation, with contributions from the gut microbiome. A futuristic model depends on harnessing the predictive power of plausible genetic variants, phenotype reversibility, and effective therapeutic choices based on genotype-phenotype interactions. Inverting disease phenotypes into ideal cardiovascular health metrics could improve genetic and epigenetic assessment, and form the basis of a future model for risk detection and early intervention.
Asunto(s)
Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/genética , Obesidad/diagnóstico , Obesidad/genética , Obesidad/metabolismo , Enfermedades Cardiovasculares/metabolismo , Genética de Población , Humanos , Hipertensión/complicaciones , Hipertensión/diagnóstico , Hipertensión/genética , Inflamación/complicaciones , Inflamación/diagnóstico , Inflamación/genética , Obesidad/complicaciones , Fenotipo , Polimorfismo Genético , Pronóstico , Factores de RiesgoRESUMEN
BACKGROUND: Vitamin D deficiency is an unrecognized epidemic found in India and also worldwide. Despite the high prevalence of diabetes among Indians, there is a paucity of data showing the relationship between vitamin D status and cardiometabolic disparities. In this study, we have examined the relationship between vitamin D and cardiometabolic traits in a population from India. METHODS: Circulating 25(OH)D levels were measured in 3,879 participants from the Asian Indian Diabetic Heart Study using ELISA kits. RESULTS: Vitamin D levels were significantly reduced (p < 0.0001) in both men and women with obesity. However, compared to women, serum vitamin D was consistently lower in men (p < 0.02), irrespective of the presence of obesity and type 2 diabetes. Multivariate regression revealed strong interaction of vitamin D with body mass index that resulted in increased fasting glucose (p = 0.001) and reduced homeostasis model assessment of ß-cell function (HOMA-B; p = 0.01) in normoglycemic individuals. However, in gender-stratified analysis, this association was restricted to men for both fasting glucose (p = 2.4 × 10-4) and HOMA-B (p = 0.001). CONCLUSIONS: Our findings suggest that vitamin D deficiency may significantly enhance the risk of cardiometabolic disease among Asian Indians. Future randomized trials and genetic studies are expected to clarify the underlying mechanisms for gender differences in vitamin D deficiency, and whether vitamin D-driven improvement in testosterone may contribute to beneficial cardiometabolic outcomes in men.
Asunto(s)
Enfermedades Cardiovasculares/epidemiología , Disparidades en el Estado de Salud , Síndrome Metabólico/epidemiología , Factores Sexuales , Deficiencia de Vitamina D/epidemiología , Vitamina D/sangre , Adulto , Glucemia/análisis , Índice de Masa Corporal , Enfermedades Cardiovasculares/sangre , Estudios de Casos y Controles , Estudios Transversales , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/epidemiología , Femenino , Humanos , India/epidemiología , Masculino , Síndrome Metabólico/sangre , Persona de Mediana Edad , Obesidad/sangre , Obesidad/epidemiología , Prevalencia , Factores de Riesgo , Deficiencia de Vitamina D/sangreRESUMEN
Prevailing infant and toddler feeding practices in an American Indian community were assessed to explore the feasibility of improvement by implementation of a maternal education program. A survey of prevailing nutritional practice was the basis for design of an instruction program on infant nutrition for mothers during pregnancy. Follow-up assessments provided information on feasibility, and requirements for an effective program. Failure to sustain breast-feeding, low fruit and vegetable intake, low fiber intake, consumption of sweetened beverages, low milk consumption and low vitamin D intake were identified as persisting problems. We conclude that infant and toddler feeding practices are comparable to national trends, but suboptimal and conducive to promoting early obesity and diabetes in a susceptible community. A successful education-based intervention strategy beginning in pregnancy appears feasible if psychosocial, environmental, and economic barriers can be addressed.
Asunto(s)
Dieta/etnología , Indígenas Norteamericanos , Fenómenos Fisiológicos Nutricionales del Lactante/etnología , Obesidad Infantil/etnología , Obesidad Infantil/prevención & control , Adolescente , Adulto , Peso Corporal , Lactancia Materna/etnología , Femenino , Promoción de la Salud , Humanos , Lactante , Recién Nacido , Masculino , Oklahoma , Factores SocioeconómicosRESUMEN
Background: Genome-wide polygenic risk scores (PRS) have shown high specificity and sensitivity in predicting type 2 diabetes (T2D) risk in Europeans. However, the PRS-driven information and its clinical significance in non-Europeans are underrepresented. We examined the predictive efficacy and transferability of PRS models using variant information derived from genome-wide studies of Asian Indians (AIs) (PRSAI) and Europeans (PRSEU) using 13,974 AI individuals. Methods: Weighted PRS models were constructed and analyzed on 4602 individuals from the Asian Indian Diabetes Heart Study/Sikh Diabetes Study (AIDHS/SDS) as discovery/training and test/validation datasets. The results were further replicated in 9372 South Asian individuals from UK Biobank (UKBB). We also assessed the performance of each PRS model by combining data of the clinical risk score (CRS). Results: Both genetic models (PRSAI and PRSEU) successfully predicted the T2D risk. However, the PRSAI revealed 13.2% odds ratio (OR) 1.80 [95% confidence interval (CI) 1.63-1.97; p = 1.6 × 10-152] and 12.2% OR 1.38 (95% CI 1.30-1.46; p = 7.1 × 10-237) superior performance in AIDHS/SDS and UKBB validation sets, respectively. Comparing individuals of extreme PRS (ninth decile) with the average PRS (fifth decile), PRSAI showed about two-fold OR 20.73 (95% CI 10.27-41.83; p = 2.7 × 10-17) and 1.4-fold OR 3.19 (95% CI 2.51-4.06; p = 4.8 × 10-21) higher predictability to identify subgroups with higher genetic risk than the PRSEU. Combining PRS and CRS improved the area under the curve from 0.74 to 0.79 in PRSAI and 0.72 to 0.75 in PRSEU. Conclusion: Our data suggest the need for extending genetic and clinical studies in varied ethnic groups to exploit the full clinical potential of PRS as a risk prediction tool in diverse study populations.
RESUMEN
Background: Hypertriglyceridemia is as an independent risk factor for cardiovascular disease (CVD). Apolipoprotein C-III (ApoC-III) is known to regulate triglyceride (TG) metabolism. However, the causal association between ApoC-III and CVD development is unclear. The objectives were to examine the impact of ApoC-III concentration on TG and lipoproteins and investigate the role of known rare loss-of-function APOC3 variants for modulating ApoC-III, TG concentrations and CVD risk in different ethnic groups. Methods: Plasma ApoC-III levels were measured in a multiethnic sample of 518 individuals comprising 271 Asian Indians (Sikhs), 87 Caucasians, 80 African Americans, and 80 Hispanics. Results: ApoC-III levels showed a robust association with TG in Asian Indians (r = 0.5, p = 1.1 × 10-23), Caucasians (r = 0.4, p = 7.2 × 10-4), and Hispanics (r = 0.9, p = 2.7x × 10-28). African Americans had lowest ApoC-III and TG concentrations and highest (44%) prevalence of coronary artery disease (CAD). ApoC-III levels correlated with fasting blood glucose (r = 0.25, p = 6.1 × 10-5) in Asian Indians and central adiposity in Hispanics (waist: r = 0.22, p = 0.05; waist-hip ratio: r = 0.24, p = 0.04). The carriers of rare variants IVS1-2G-A (rs373975305); A43T (rs147210663) and IVS3 + 1G-T (rs140621530) showed high TG but not low ApoC-III levels in Asian Indians and Caucasians. Conclusion: These results highlight the challenges of generalizing antisense ApoC-III inhibition for treating atherosclerotic disease in dyslipidemia that may benefit only specific sub-populations. The observed ethnic differences in ApoC-III concentrations and CAD risk factors, emphasize in-depth genetic and metabolomics evaluations on diverse ancestries.
RESUMEN
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) an important regulator of bone homeostasis, mediates its actions by binding to the vitamin D receptor (VDR), a nuclear transcription factor. Mutations in the VDR cause the rare genetic disease hereditary vitamin D resistant rickets (HVDRR). In this study, we examined two unrelated young female patients who exhibited severe early onset rickets, hypocalcemia, and hypophosphatemia. Both patients had partial alopecia but with different unusual patterns of scant hair. Sequencing of the VDR gene showed that both patients harbored the same unique nonsense mutation that resulted in a premature stop codon (R50X). Skin fibroblasts from patient #1 were devoid of VDR protein and 1,25(OH)2D3 treatment of these cells failed to induce CYP24A1 gene expression, a marker of 1,25(OH)2D3 action. In conclusion, we identified a novel nonsense mutation in the VDR gene in two patients with HVDRR and alopecia. The mutation truncates the VDR protein and causes 1,25(OH)2D3 resistance.
Asunto(s)
Alopecia/genética , Codón sin Sentido , Receptores de Calcitriol/genética , Raquitismo/genética , Biomarcadores/metabolismo , Preescolar , Análisis Mutacional de ADN , Resistencia a Medicamentos , Inducción Enzimática/efectos de los fármacos , Femenino , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Fibroblastos/patología , Expresión Génica/efectos de los fármacos , Humanos , Receptores de Calcitriol/metabolismo , Piel/efectos de los fármacos , Piel/metabolismo , Piel/patología , Esteroide Hidroxilasas/biosíntesis , Vitamina D/análogos & derivados , Vitamina D/farmacología , Vitamina D/uso terapéutico , Vitamina D3 24-HidroxilasaRESUMEN
A 4-10/12 year-old boy presented with tall stature and advanced secondary sexual characteristics. His bone age was 13 years giving him a height prediction of 147 cm. An initial 11-deoxycortisol level of 13,770 ng/dl and associated hypertension suggested the diagnosis of 11-hydroxylase deficiency, which was confirmed by dexamethasone suppression and genotyping. Treatment strategy was based on the premise that known hypothalamic priming resulting in early pubertal development could be averted by delaying puberty with leuprolide; also that effects of hydrocortisone and leuprolide on attenuating growth could be counteracted by growth hormone. The combined treatment resulted in a final height at age 12 years which was 25.4 cm greater than predicted, and bone density above average. We conclude that delaying puberty until an appropriate age, offsetting growth suppression, and improving bone mineralization can be effectively achieved using glucocorticoids, leuprolide and growth hormone in patients with 11-hydroxylase deficiency.
Asunto(s)
Hiperplasia Suprarrenal Congénita/tratamiento farmacológico , Hormona de Crecimiento Humana/uso terapéutico , Hidrocortisona/uso terapéutico , Leuprolida/administración & dosificación , Hiperplasia Suprarrenal Congénita/enzimología , Hiperplasia Suprarrenal Congénita/genética , Estatura/efectos de los fármacos , Estatura/fisiología , Densidad Ósea/efectos de los fármacos , Densidad Ósea/fisiología , Niño , Preparaciones de Acción Retardada , Genotipo , Humanos , Hipertensión/tratamiento farmacológico , Hipertensión/fisiopatología , Estudios Longitudinales , Masculino , Pubertad Precoz/prevención & control , Esteroide 11-beta-Hidroxilasa/genética , Esteroide 11-beta-Hidroxilasa/metabolismoRESUMEN
Children and adolescents with obesity are increasingly referred to the pediatric endocrinology clinic at OU Children's Hospital for evaluation and initiation of preventive measures. During the summer of 2004 we conducted a retrospective review of cases to determine the prevalence of fasting insulin resistance and dyslipidemia; to study associations and differences due to ethnic background; and compare values with similar patients seen at four Indian Health Service clinics. We observed the highest prevalence of dyslipidemia in Caucasian youth. The prevalence of high fasting glucose and mean glucose values were higher in the obese Native American youth than in African Americans or Caucasians. The elevated glucose levels in young Native Americans may be associated with their increased risk for type 2 diabetes compared to other races; but Caucasians are more prone to dyslipidemia. Effective methods are needed to detect, prevent and treat diabetes and cardiovascular risk in children and adolescents.
Asunto(s)
Etnicidad , Hipoglucemia/sangre , Resistencia a la Insulina , Lípidos/sangre , Obesidad , Adolescente , Humanos , Oklahoma , Estudios RetrospectivosRESUMEN
Vitamin D deficiency is implicated in multiple disease conditions and accumulating evidence supports that the variation in serum vitamin D (25(OH)D) levels, including deficiency, is under strong genetic control. However, the underlying genetic mechanism associated with vitamin 25(OH)D concentrations is poorly understood. We earlier reported a very high prevalence of vitamin D deficiency associated with an increased risk for type 2 diabetes and obesity in a Punjabi Sikh diabetic cohort as part of the Asian Indian diabetic heart study (AIDHS). Here we have performed the first genome-wide association study (GWAS) of serum 25(OH)D on 3538 individuals from this Punjabi Sikh population. Our discovery GWAS comprised of 1387 subjects followed by validation of 24 putative SNPs (P<10(-4)) using an independent replication sample (n=2151) from the same population by direct genotyping. A novel locus at chromosome 20p11.21 represented by rs2207173 with minor allele frequency (MAF) 0.29, [ß=-0.13, p=4.47×10(-9)] between FOXA2 and SSTR4 was identified to be associated with 25(OH)D levels. Another suggestive association signal at rs11586313 (MAF 0.54) [ß=0.90; p=1.36×10(-6)] was found within the regulatory region of the IVL gene on chromosome 1q21.3. Additionally, our study replicated 3 of 5 known GWAS genes associated with 25(OH)D concentrations including GC (p=0.007) and CYP2R1 (p=0.019) reported in Europeans and the DAB1 (p=0.003), reported in Hispanics. Identification of novel association signals in biologically plausible regions with 25(OH)D metabolism will provide new molecular insights on genetic drivers of vitamin D status and its implications in health disparities.
Asunto(s)
Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/genética , Hidroxicolecalciferoles/sangre , Población Blanca/genética , Adulto , Anciano , Estudios de Casos y Controles , Diabetes Mellitus Tipo 2/epidemiología , Femenino , Variación Genética , Estudio de Asociación del Genoma Completo , Genotipo , Humanos , India/epidemiología , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido SimpleRESUMEN
Because Native Americans are predisposed to obesity and type 2 diabetes associated with coronary artery disease, we assessed whether apoC-III bound to apoB-containing (LpB:C-III) and apoA-containing (LpA:C-III) lipoproteins, total apoC-III, apoB, and plasma lipids are associated with insulin resistance, body mass index (BMI), and waist circumference in Cherokee children and adolescents aged 5 to 19 years (n = 975). A cross-sectional analysis was done to determine associations of the lipoproteins with the homeostasis index (HOMA-IR) and BMI. When the data were grouped by quartiles for HOMA-IR and separated by three 5-year age groups (5-9, 10-14, and 15-19 years), the trend for LpB:C-III, triglyceride, and BMI z score to increase was significant for all age groups and both genders (P < .001). The trend to increase LpB:C-III with age was greater in boys (P < .0001) than in girls (P < .05) who tended to plateau after the age of 10 years. In contrast, the ratio of LpA:C-III to LpB:C-III decreased and the decrease was greater in boys (P < .0001) than girls (P < .01). Body mass index z score and waist circumference were correlated with LpB:C-III, triglyceride, apoB, and non-high-density lipoprotein cholesterol within each gender (P < .001). In multiple regression models, LpB:C-III, the dependent variable, was associated with HOMA-IR for both genders. We conclude that increases in LpB:C-III in childhood and adolescence are associated with insulin resistance and obesity supporting the need for prevention programs.
Asunto(s)
Apolipoproteínas B/metabolismo , Apolipoproteínas C/metabolismo , Indígenas Norteamericanos , Resistencia a la Insulina/fisiología , Lipoproteínas/metabolismo , Adolescente , Adulto , Apolipoproteína C-III , Glucemia/metabolismo , Estatura , Índice de Masa Corporal , Peso Corporal/fisiología , Niño , Femenino , Humanos , Insulina/sangre , Lípidos/sangre , Masculino , Caracteres Sexuales , Relación Cintura-CaderaRESUMEN
OBJECTIVE: To report prevalence rates of acanthosis nigricans (AN) and hyperinsulinemia and the association of AN with hyperinsulinemia compared with other known or suspected risk factors for type 2 diabetes in young American Indians. RESEARCH DESIGN AND METHODS: A random sample of Cherokee Nation members aged 5-40 years was invited to participate in the Cherokee Diabetes Study, a cross-sectional study of type 2 diabetes and its risk factors in a young American Indian population. Data were collected by personal interview, medical history, physical examination (including anthropometric and blood pressure measurements and examination of the neck for AN), and laboratory analyses of blood specimens. Levels of insulin, lipids, and glucose were measured on fasting blood specimens. Diabetes status was determined according to the American Diabetes Association criteria. RESULTS: A total of 2,205 participants were examined. Overall prevalence rates for AN and hyperinsulinemia were 34.2 and 47.2%, respectively. In general, the rates for both increased with age and degree of Indian heritage and were higher in female subjects, overweight/obese individuals, those with type 2 diabetes, and those with a parental history of type 2 diabetes. In addition, both had significantly higher age- and sex-adjusted means for selected known or suspected risk factors for type 2 diabetes. AN remained significantly associated with hyperinsulinemia (P = 0.0001) in multivariate analysis. CONCLUSIONS: AN is independently associated with hyperinsulinemia and therefore may be useful as an early indicator of high risk for diabetes.
Asunto(s)
Acantosis Nigricans/epidemiología , Diabetes Mellitus Tipo 2/epidemiología , Hiperinsulinismo/epidemiología , Indígenas Norteamericanos/genética , Acantosis Nigricans/complicaciones , Adolescente , Adulto , Glucemia/metabolismo , Presión Sanguínea , Niño , Preescolar , Estudios Transversales , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/fisiopatología , Intolerancia a la Glucosa/sangre , Intolerancia a la Glucosa/epidemiología , Humanos , Hiperinsulinismo/complicaciones , Insulina/sangre , Análisis de los Mínimos Cuadrados , Lípidos/sangre , Lipoproteínas/sangre , Oklahoma/epidemiología , Prevalencia , Factores de RiesgoRESUMEN
Secondary dyslipidemia with predominant hypertriglyceridemia may occur as a consequence of both common and rare causes. After accounting for obesity and associated insulin resistance, clinicians should carefully consider other contributing factors and conditions. Genetic background and causative factors prevail during gestation, infancy, and childhood and continue in adults. Elevations in triglyceride (TG) are associated with transfer of TG to high-density lipoprotein (HDL) and low-density lipoprotein (LDL) resulting in lipolysis, HDL degradation, and formation of atherogenic LDL particles. Defining and treating the underlying cause is the first step toward restoring the lipids and lipoproteins to normal, especially in cases with severe hypertriglyceridemia, who are at risk for acute pancreatitis. Disorders involving the liver, kidney, endocrine, and immune systems and medications need to be considered. Rare diseases such as lipodystrophy and glycogen storage disease are particularly challenging, and there have been promising new developments. Treatment depends on the severity; prevention of acute pancreatitis being a priority in severe cases and lifestyle modification being a foundation for general management followed by targeting TG and predictors of coronary artery disease such as LDL cholesterol and non-HDL cholesterol, when they exceed cutpoints.
Asunto(s)
Hipertrigliceridemia/patología , Adolescente , Niño , Predisposición Genética a la Enfermedad , Humanos , Hipertrigliceridemia/etiología , Hipertrigliceridemia/genética , Hipertrigliceridemia/terapia , Modelos BiológicosRESUMEN
BACKGROUND AND OBJECTIVES: Apolipoprotein E (APOE) gene polymorphisms have been examined extensively in multiple global populations particularly due to their crucial role in lipid metabolism and cardiovascular disease. However, the overall contribution of APOE polymorphisms in type 2 diabetes (T2D) and coronary artery disease (CAD) in South Asians is still under-investigated. The objectives of this investigation were: 1) to evaluate the distribution of APOE polymorphisms in a large diabetic case-control sample from South Asia, 2) to examine the impact of APOE polymorphisms on quantitative risk factors of T2D and CAD, and 3) to explore the contribution of APOE genotypes in the response to anti-diabetic therapy. SUBJECTS AND METHODS: A total of 3564 individuals (1956 T2D cases and 1608 controls) used in this study were part of the Asian Indian Diabetic Heart Study/Sikh Diabetes Study (AIDHS/SDS). We assessed the association of APOE polymorphisms with T2D, CAD and cardiometabolic traits using logistic and linear regression analysis. RESULTS AND CONCLUSIONS: No significant differences in the distribution of APOE genotypes were observed between T2D and CAD cases and controls. The APOE4 genotype carriers had moderately higher diastolic blood pressure (BP) (p=0.022), and lower HDL-cholesterol (p=0.026) compared to E4 non-carriers. Overall, the APOE genotype was not a significant predictor of cardiometabolic disease in this population. Further stratification of data from diabetic patients by APOE genotypes and anti-hyperglycemic agents revealed a significant (~23%) decrease in 2-hour glucose (p=0.004) and ~7% decrease in systolic BP (p<0.001) among APOE4 carriers compared to non-carriers on metformin and sulphonylurea (SU) combination therapy, and no such differences were seen in patients on other agents. Our preliminary findings point to the need for evaluating population-specific genetic variation and its interactions with therapeutic effects.
Asunto(s)
Apolipoproteína E3/genética , Enfermedad de la Arteria Coronaria/complicaciones , Diabetes Mellitus Tipo 2/genética , Resistencia a Medicamentos , Predisposición Genética a la Enfermedad , Hipoglucemiantes/uso terapéutico , Polimorfismo Genético , Alelos , Apolipoproteína E3/metabolismo , Estudios de Casos y Controles , Estudios de Cohortes , Enfermedad de la Arteria Coronaria/epidemiología , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Angiopatías Diabéticas/epidemiología , Quimioterapia Combinada , Femenino , Frecuencia de los Genes , Estudios de Asociación Genética , Humanos , Hiperglucemia/prevención & control , Hiperlipidemias/complicaciones , Hiperlipidemias/epidemiología , Hiperlipidemias/prevención & control , India/epidemiología , Masculino , Metformina/uso terapéutico , Persona de Mediana Edad , Factores de Riesgo , Compuestos de Sulfonilurea/uso terapéuticoRESUMEN
Generalized lipodystrophy is characterized by adipose tissue absence, hypoleptinemia, hypertriglyceridemia, insulin resistance, diabetes, hepatomegaly, and nonalcoholic steatohepatitis. In the course of recruiting patients for treatment with recombinant leptin, we were struck by the frequency and severity of proteinuria. We evaluated 25 patients with generalized lipodystrophy. Eighteen were treated with recombinant leptin, and we have followed 15 on leptin for 4-36 months. We followed renal parameters at baseline and during follow-up visits. Renal biopsies were performed as clinically indicated. At baseline, 22 of 25 patients (88%) had elevated urine albumin excretion (>30 mg/24 h), 15 (60%) had macroalbuminuria (>300 mg/24 h), and five (20%) had nephrotic-range proteinuria (>3500 mg/24 h). Twenty-three (92%) had elevated creatinine clearance (>125 ml/min.1.73 m(2)). Eleven of 15 patients (73%) treated with recombinant leptin exhibited reduction in proteinuria, associated with reduction of hyperfiltration. Four patients who did not improve are discussed individually. Renal biopsy findings were remarkable for focal segmental glomerulosclerosis in four patients, membranoproliferative glomerulonephritis in two patients, and diabetic nephropathy in one patient. In conclusion, generalized lipodystrophy is associated with proteinuria and unique renal pathologies, including focal segmental glomerulosclerosis and membranoproliferative glomerulonephritis. The majority treated with recombinant leptin demonstrated reduction in proteinuria and hyperfiltration.
Asunto(s)
Enfermedades Renales/complicaciones , Enfermedades Renales/fisiopatología , Leptina/uso terapéutico , Lipodistrofia/congénito , Lipodistrofia/complicaciones , Proteinuria/etiología , Adolescente , Adulto , Anciano , Biopsia , Niño , Creatinina/sangre , Creatinina/orina , Nefropatías Diabéticas/complicaciones , Nefropatías Diabéticas/patología , Femenino , Glomerulonefritis Membranoproliferativa/complicaciones , Glomerulonefritis Membranoproliferativa/patología , Glomeruloesclerosis Focal y Segmentaria/complicaciones , Glomeruloesclerosis Focal y Segmentaria/patología , Humanos , Riñón/efectos de los fármacos , Riñón/patología , Enfermedades Renales/patología , Lipodistrofia/tratamiento farmacológico , Lipodistrofia/patología , Masculino , Persona de Mediana Edad , Proteinuria/metabolismo , Proteínas Recombinantes/uso terapéutico , SíndromeRESUMEN
PURPOSE: To estimate the prevalence of type 2 diabetes and impaired fasting glucose (IFG) and to study several potential risk factors for type 2 diabetes among Oklahoma Cherokees aged 5 to 40 years. METHODS: A random sample of 2205 members of the Cherokee Nation of Oklahoma aged 5 to 40 years was recruited. Demographic, clinical, and laboratory data were collected. Type 2 diabetes and IFG were determined using the 1997 American Diabetes Association (ADA) criteria. Relationships between type 2 diabetes and potential risk factors were examined by univariate and multivariate regression methods. RESULTS: According to ADA criteria, the age-adjusted prevalence proportions of type 2 diabetes were 4.3% in females and 4.8% in males. Among the 89 individuals who had type 2 diabetes, 31 were newly diagnosed. Thirty-two (1.5%, 18 females and 14 males) were found to have IFG. The prevalence of type 2 diabetes and IFG increased with age, number of parents with diabetes, obesity, degree of Indian heritage, high triglyceride value, and low HDL cholesterol. CONCLUSIONS: The increasing prevalence of type 2 diabetes in young American Indians is alarming. The findings must be disseminated to the Indian communities and their health care providers. Preventive measures and early detection programs must be designed and implemented for children and adolescents in this population.
Asunto(s)
Diabetes Mellitus Tipo 2/etnología , Intolerancia a la Glucosa/etnología , Indígenas Norteamericanos/estadística & datos numéricos , Adolescente , Adulto , Niño , Preescolar , Diabetes Mellitus Tipo 2/epidemiología , Femenino , Intolerancia a la Glucosa/epidemiología , Humanos , Entrevistas como Asunto , Masculino , Prevalencia , Factores de Riesgo , Estados Unidos/epidemiologíaRESUMEN
In Oklahoma since the early 1990s, all newborns have been screened for four metabolic conditions: phenylketonuria, hypothyroidism, galactosemia and hemoglobinopathies. In 2002, 38 affected babies were diagnosed and one expects they are saved from the complications of late diagnosis such as mental retardation or death from sepsis. With advances in genetics and improved biochemical assays, 86% of states now screen for more disorders than Oklahoma, up to 37 in Mississippi. Six recent patient vignettes illustrate the mortality and morbidity of conditions that are screened for elsewhere but not in Oklahoma. In 2001, the Oklahoma Genetics Advisory Council recommended adding three disorders and the State Health Department forecasts that implementation may be complete in 2007. For now, when a patient asks, "Will my baby be screened for as many metabolic conditions as possible?", two answers represent either the public health or the private health care view. The public health answer is, "The state requires screening for four conditions." The health care system answer is, "We can work with you to get 44 conditions tested for, but it will cost money, may not be reimbursed, and has not been proven effective when done on an individual basis." This dilemma, not unique to newborn screening, might be resolved if professional and public opinion strongly supported early expansion.
Asunto(s)
Enfermedades Genéticas Congénitas/diagnóstico , Tamizaje Neonatal/normas , Atención a la Salud/normas , Femenino , Enfermedades Genéticas Congénitas/economía , Humanos , Lactante , Recién Nacido , Masculino , Tamizaje Neonatal/economía , Oklahoma , Práctica PrivadaRESUMEN
The prevalence of childhood obesity in the United States has increased dramatically in recent years, doubling in the last 20 years, and is expected to result in a major public health crisis. This epidemic has left no race, socioeconomic status, or age unaffected. Children in Oklahoma are no exception; according to the Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, 25% of Oklahoma's adolescents are at risk for overweight or are overweight. In order to address this problem, efforts are underway nationally to institute preventive measures for childhood obesity and its comorbid conditions.
Asunto(s)
Costo de Enfermedad , Obesidad , Adolescente , Niño , Preescolar , Humanos , Obesidad/complicaciones , Obesidad/economía , Obesidad/psicología , Estados UnidosRESUMEN
This review provides a translational and unifying summary of metabolic syndrome genetics and highlights evidence that genetic studies are starting to unravel and untangle origins of the complex and challenging cluster of disease phenotypes. The associated genes effectively express in the brain, liver, kidney, arterial endothelium, adipocytes, myocytes, and ß cells. Progression of syndrome traits has been associated with ectopic lipid accumulation in the arterial wall, visceral adipocytes, myocytes, and liver. Thus, it follows that the genetics of dyslipidemia, obesity, and nonalcoholic fatty liver disease are central in triggering progression of the syndrome to overt expression of disease traits and have become a key focus of interest for early detection and for designing prevention and treatments. To support the "birds' eye view" approach, we provide a road-map depicting commonality and interrelationships between the traits and their genetic and environmental determinants based on known risk factors, metabolic pathways, pharmacologic targets, treatment responses, gene networks, pleiotropy, and association with circadian rhythm. Although only a small portion of the known heritability is accounted for and there is insufficient support for clinical application of gene-based prediction models, there is direction and encouraging progress in a rapidly moving field that is beginning to show clinical relevance.